ANNUAL REPORT FY23 3 Nyrada Overview Our vision To become a high growth pharmaceutical discovery and development company specialising in early-stage drug development of novel treatments. Our strategy To develop treatments for diseases where there is an unmet clinical need, or where current treatments are suboptimal, and to monetise the value of these treatments through advancing highly optimised drug candidates towards out-licensing. Advancing our strategy Delivering upon our vision and strategy through our current two lead drug candidates: a PKSK9 inhibitor for cholesterol lowering and a TRPC ion channel blocker for secondary brain injury treatment.
RkJQdWJsaXNoZXIy MjE2NDg3